Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome.
Document Type
Article
Publication Date
1-1-2021
Publication Title
Epilepsy Behav Rep
Keywords
california; newport beach; hoag
Abstract
A 20-year-old woman with Dravet syndrome and multiple prior episodes of status epilepticus presented to our hospital in November 2018 in super-refractory status epilepticus. After 5 weeks of unsuccessful continuous treatment with anesthetics, including pentobarbital and ketamine, we sought and were granted an emergency approval by the United States Food and Drug Administration to administer fenfluramine, an investigational new drug, to this patient. One week of treatment with fenfluramine at 0.4 mg/kg/day was ineffective. The dose of fenfluramine was titrated to 0.7 mg/kg/day, and after 1 week, electrographic seizures ceased. One week later, the patient was seizure-free and off all anesthetic agents. Add-on treatment with fenfluramine was continued with no further episodes of status epilepticus and >90% reduction in tonic-clonic seizures. This case report illustrates the potential for fenfluramine to prevent reoccurrence of status epilepticus and to manage super-refractory status epilepticus in patients with Dravet syndrome.
Clinical Institute
Neurosciences (Brain & Spine)
Department
Neurosciences
Department
Pharmacy
Recommended Citation
Millett, David and Pach, Suzanne, "Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome." (2021). Articles, Abstracts, and Reports. 5041.
https://digitalcommons.providence.org/publications/5041
